GET DAILY SIGNALSWhy Is ImmunityBio (IBRX) Stock Down -9.26% Today?
Key Takeaways
- Shares of ImmunityBio fell roughly 9.26% on Monday, sliding from a prior close of $9.18 to about $8.33 in intraday trading.
- The decline was driven primarily by profit-taking after a blistering 2026 rally that has left the stock up more than 360% year to date.
- A weak broader biotechnology tape amplified the selling, with sector ETFs such as XBI and IBB trading lower and dragging the name down alongside peers.
- The move came despite positive fundamentals, including last week's expanded FDA approval for Anktiva and encouraging long-term Phase 3 clinical data.
- Traders are watching technical support levels and the company's upcoming third-quarter earnings report, expected in early November.
Opening Summary
ImmunityBio, Inc. (IBRX), a San Diego-based commercial-stage immunotherapy company whose lead product, Anktiva, treats BCG-unresponsive non-muscle invasive bladder cancer, saw its shares drop sharply in Monday's session. The stock traded down about 9.26% to roughly $8.33, versus a previous close of $9.18. The decline extended a pullback that began late last week, as investors locked in gains following a dramatic multi-month run and a wave of positive company news that had already been priced into the shares.
Profit-Taking After a Blockbuster Rally
The most immediate driver behind the slide was a classic sell-the-news reaction. IBRX has been one of the strongest performers in the biotech space in 2026, rising more than 360% year to date and roughly 255% over the trailing 52 weeks. After such a steep ascent, momentum-oriented traders and longer-term holders alike have increasingly used strength as an opportunity to book profits, even as the company's underlying news flow remained favorable.
Notably, the selling intensified without any fresh negative company-specific announcement. Instead, market participants cited the stock's extended valuation and overheated technical posture as reasons to trim exposure, with the pullback reflecting positioning rather than a deterioration in business fundamentals.
Weak Biotechnology Sector Adds Pressure
The decline also aligned with broader weakness across the biotechnology complex. Leading biotech exchange-traded funds, including the SPDR S&P Biotech ETF (XBI) and the iShares Biotechnology ETF (IBB), traded lower Monday, weighing on speculative and high-beta names such as IBRX. When sector sentiment sours, stocks with the largest recent gains and elevated valuations are often the first to give back ground, and ImmunityBio fit that profile precisely.
Positive Catalysts Could Not Halt the Slide
The day's losses were notable because they occurred despite a string of constructive developments. Last week, the U.S. Food and Drug Administration expanded the approved indication for Anktiva in combination with BCG to include patients with BCG-unresponsive non-muscle invasive bladder cancer presenting with both papillary tumors and carcinoma in situ. The company also published long-term data from its Phase 2/3 QUILT-3.032 study showing a 71% complete response rate and an 84% cystectomy-avoidance rate at three years.
Analysts responded positively, with Jefferies raising its price target to $14 from $12 and Piper Sandler lifting its target to $16 from $12, both maintaining bullish ratings. Yet with these catalysts now fully reflected in the share price, buyers were scarce Monday, and the stock continued to fade.
Market Context and Trading Activity
Trading volume was elevated relative to normal levels, consistent with active distribution as sellers moved to the sidelines. The decline broke the stock below its prior session's low and pushed it back toward its 50-day moving average, a level that technical traders monitor closely for signs of near-term stabilization. The move also stood in contrast to the stock's behavior for much of the year, when favorable clinical and regulatory headlines had repeatedly propelled the shares higher.
Despite Monday's setback, the stock remains well above its 52-week low of $1.95 and retains a multi-billion-dollar market capitalization, underscoring how far it has climbed over the past year.
What Comes Next for IBRX
Investors will now look to ImmunityBio's third-quarter earnings, currently expected in early November, for evidence that Anktiva's commercial ramp remains on track. Continued sequential revenue growth and updates on international launches across Europe and the Middle East will be closely scrutinized. At the same time, the stock's elevated valuation relative to sales leaves it vulnerable to further bouts of volatility if sentiment in the broader biotech sector remains cautious or if any pipeline updates disappoint.
Risks include execution on global commercialization, competitive dynamics in the bladder cancer market, and the inherent binary nature of clinical-stage programs. While the long-term narrative around Anktiva remains intact, Monday's action illustrates that even strongly trending stocks can experience sharp, sentiment-driven corrections.
Trending AI Robots
For traders seeking a more systematic approach to navigating volatile names like IBRX, Tickeron's Trending AI Robots page offers a curated view of its strongest-performing AI trading bots. Tickeron provides hundreds of AI-driven trading bots covering thousands of tickers, but only those delivering standout results under current market conditions are featured in this section. The bots vary by strategy, timeframe, performance metrics, and the symbols they trade, allowing users to explore automated approaches aligned with their own objectives.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Contributor
Financial writer and active order flow futures trader with a focus on fundamental analysis, macroeconomic factors, and equity research. I make in-depth blogs on stocks and ETFs, bridging the gap between raw market data and real-world trading decisions.
Aroon Indicator for IBRX shows an upward move is likely
IBRX's Aroon Indicator triggered a bullish signal on October 14, 2026. Tickeron's A.I.dvisor detected that the AroonUp green line is above 70 while the AroonDown red line is below 30. When the up indicator moves above 70 and the down indicator remains below 30, it is a sign that the stock could be setting up for a bullish move. Traders may want to buy the stock or look to buy calls options. A.I.dvisor looked at 123 similar instances where the Aroon Indicator showed a similar pattern. In 115 of the 123 cases, the stock moved higher in the days that followed. This puts the odds of a move higher at 90%.
Technical Analysis (Indicators)
Bullish Trend Analysis
IBRX moved above its 50-day moving average on September 11, 2026 date and that indicates a change from a downward trend to an upward trend.
Following a +2.04% 3-day Advance, the price is estimated to grow further. Considering data from situations where IBRX advanced for three days, in 209 of 241 cases, the price rose further within the following month. The odds of a continued upward trend are 87%.
Bearish Trend Analysis
The 10-day RSI Indicator for IBRX moved out of overbought territory on October 06, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 20 similar instances where the indicator moved out of overbought territory. In 19 of the 20 cases, the stock moved lower in the following days. This puts the odds of a move lower at 90%.
The Stochastic Oscillator may be shifting from an upward trend to a downward trend. In 43 of 49 cases where IBRX's Stochastic Oscillator exited the overbought zone, the price fell further within the following month. The odds of a continued downward trend are 88%.
The Momentum Indicator moved below the 0 level on October 16, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on IBRX as a result. In 87 of 98 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 89%.
The Moving Average Convergence Divergence Histogram (MACD) for IBRX turned negative on October 16, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 54 similar instances when the indicator turned negative. In 44 of the 54 cases the stock turned lower in the days that followed. This puts the odds of success at 81%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where IBRX declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 88%.
IBRX broke above its upper Bollinger Band on October 02, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
Fundamental Analysis (Ratings)
The Tickeron Valuation Rating of 9 (best 1 - 100 worst) indicates that the company is seriously undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (-9.296) is normal, around the industry mean (2.835). P/E Ratio (-9.663) is within average values for comparable stocks, (-0.607). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (135.264) among similar stocks. P/S Ratio (47.847) is also within normal values, averaging (438.009).
The Tickeron Price Growth Rating for this company is 34 (best 1 - 100 worst), indicating steady price growth. IBRX’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Seasonality Score of 40 (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron PE Growth Rating for this company is 46 (best 1 - 100 worst), pointing to average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron SMR rating for this company is 100 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. IBRX’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
a producer of cancer treatment products
Industry Biotechnology